Fludrocortisone (Florinef): Uses, Dosing, Side Effects, and How It Compares to Other Corticosteroids

What Is Fludrocortisone and How Does It Work?

Fludrocortisone is a synthetic steroid that binds selectively to mineralocorticoid receptors in the renal collecting duct, sweat glands, and colon. Receptor binding triggers transcription of epithelial sodium channel (ENaC) subunits, increasing luminal sodium reabsorption and driving passive water retention while excreting potassium and hydrogen ions. The net result is expanded extracellular volume and raised blood pressure, effects that replicate those of the adrenal hormone aldosterone [1].

The drug's chemical backbone is identical to cortisol except for a 9-alpha-fluorine substitution. That single fluorine atom raises mineralocorticoid receptor affinity roughly 125-fold compared with hydrocortisone while keeping glucocorticoid activity at approximately 10 times that of hydrocortisone [2]. At standard replacement doses of 0.05 to 0.1 mg/day, glucocorticoid effects are clinically minor. At doses exceeding 0.2 mg/day, Cushingoid side effects become a measurable concern.

Fludrocortisone does not correct the cortisol deficit present in adrenal insufficiency. It works alongside a glucocorticoid, most often hydrocortisone 15 to 25 mg/day in divided doses, to cover both hormonal axes simultaneously [3].

FDA-Approved Indications

The FDA approved fludrocortisone acetate tablets (NDA 005888) for two indications: partial adrenocortical insufficiency and salt-losing adrenogenital syndrome (congenital adrenal hyperplasia, salt-wasting form) [4]. Both conditions share the pathophysiology of absent or severely reduced aldosterone secretion, leading to sodium wasting, volume depletion, and dangerously low blood pressure if left untreated.

Primary adrenal insufficiency (Addison disease). Autoimmune destruction of the adrenal cortex eliminates both cortisol and aldosterone production. Fludrocortisone 0.05 to 0.1 mg once daily restores mineralocorticoid activity. The Endocrine Society's 2016 Clinical Practice Guideline on Adrenal Insufficiency states: "We recommend that all patients with primary AI receive mineralocorticoid replacement with fludrocortisone" [5].

Salt-wasting congenital adrenal hyperplasia (CAH). Deficiency of 21-hydroxylase (CYP21A2) blocks aldosterone synthesis. Infants present with life-threatening salt-wasting crises within the first two weeks of life. Fludrocortisone 0.05 to 0.1 mg/day (adjusted by weight in neonates) combined with sodium chloride supplementation is the standard of care per the Endocrine Society's 2018 CAH guideline [6].

Off-Label Uses Supported by Evidence

Beyond its two approved indications, fludrocortisone is commonly used off-label for conditions driven by low circulating volume or autonomic failure.

Orthostatic hypotension. A 2017 systematic review in the Journal of the American Geriatrics Society found that fludrocortisone reduced orthostatic blood-pressure drop by a mean of 10 to 15 mmHg systolic in patients with neurogenic orthostatic hypotension, though effect sizes varied by etiology [7]. Doses of 0.1 to 0.3 mg/day are typical, with hypokalemia monitoring every 4 to 6 weeks at initiation.

Postural orthostatic tachycardia syndrome (POTS). Small randomized data support volume expansion with fludrocortisone 0.1 mg/day as first-line pharmacotherapy alongside high sodium intake and compression garments, though the evidence base remains limited to trials of fewer than 100 participants [8].

Secondary and tertiary adrenal insufficiency. Secondary AI (pituitary failure) and tertiary AI (exogenous steroid suppression) rarely require mineralocorticoid replacement because aldosterone secretion is regulated partly by the renin-angiotensin system and is usually preserved. Fludrocortisone is added selectively when plasma renin activity remains elevated despite glucocorticoid replacement [9].

Standard Dosing and Administration

Oral fludrocortisone acetate 0.1 mg tablets are taken once daily, typically in the morning to align with the physiological aldosterone peak [4]. The prescribing range is 0.05 to 0.2 mg/day in adults. Pediatric dosing in CAH is weight-based: approximately 0.05 to 0.1 mg/day in neonates and infants, tapered as body surface area increases with age [6].

Dose adjustments rely on clinical and biochemical targets rather than a fixed schedule:

• Blood pressure should normalize to age-appropriate values without supine hypertension.
• Plasma renin activity (PRA) is the most sensitive pharmacodynamic marker. A PRA in the mid-to-upper normal range indicates adequate mineralocorticoid replacement; suppressed PRA suggests over-replacement [5].
• Serum potassium should remain between 3.5 and 5.0 mEq/L.
• Dose may need upward adjustment during summer months or in hot climates because sweat losses increase sodium demand.

Tablets should not be crushed or split; the acetate salt is stable at room temperature [4]. No dose adjustment is required for renal impairment per the FDA label, but patients with stage 3b chronic kidney disease or worse warrant closer blood pressure and potassium monitoring given reduced renal tubular reserve [10].

Side Effects and Safety Profile

Hypertension and edema. Over-replacement expands plasma volume excessively, raising blood pressure and causing peripheral edema. A retrospective cohort of 116 patients with Addison disease published in the European Journal of Endocrinology found that 31% had blood pressure above 140/90 mmHg at standard replacement doses, with improvement after dose reduction [11].

Hypokalemia. Renal potassium wasting is dose-dependent. Serum potassium should be checked at each dose change and every 6 months during stable maintenance. Dietary potassium supplementation or co-prescription of a potassium-sparing agent may be needed when doses exceed 0.15 mg/day [5].

Glucocorticoid adverse effects. At doses above 0.2 mg/day, fludrocortisone's intrinsic glucocorticoid activity may contribute to weight gain, glucose intolerance, or bone loss, particularly in patients already receiving hydrocortisone or prednisone concurrently [2].

Headache and dizziness. Both are reported early in treatment and often reflect volume changes rather than a direct drug effect. Most cases resolve within the first 2 to 4 weeks as extracellular volume equilibrates [4].

Contraindications. Systemic fungal infections represent the only absolute contraindication listed in the FDA label [4]. Relative contraindications include decompensated heart failure, severe hypertension, and conditions requiring sodium restriction.

Drug Interactions

Fludrocortisone interacts with several drug classes that clinicians prescribing adrenal replacement therapy routinely encounter [12]:

• Potassium-depleting diuretics (thiazides, loop diuretics): additive hypokalemia risk.
• NSAIDs: blunt the antihypertensive effect and may worsen sodium retention.
• Enzyme-inducing drugs (rifampicin, phenytoin, carbamazepine): accelerate fludrocortisone metabolism via CYP3A4, potentially reducing efficacy; dose may need to be increased.
• Salicylates at high doses: reduced salicylate plasma levels reported with concurrent mineralocorticoid therapy.
• Anticoagulants: corticosteroids may either enhance or attenuate warfarin effect; INR monitoring is required at initiation.

Grapefruit juice is not a clinically significant concern for fludrocortisone because its absorption is not primarily CYP3A4-mediated [12].

How Fludrocortisone Compares to Other Corticosteroids

Corticosteroids span a wide potency spectrum across two receptor axes. The table below organizes the five drugs most relevant to this article by their relative glucocorticoid and mineralocorticoid potencies, using hydrocortisone as the reference compound.

| Drug | Relative Glucocorticoid Potency | Relative Mineralocorticoid Potency | Approximate Half-Life | |---|---|---|---| | Hydrocortisone (Cortef) | 1 | 1 | 8 to 12 hours | | Fludrocortisone (Florinef) | 10 | 125 | 18 to 36 hours (biological) | | Prednisone | 4 | 0.8 | 12 to 36 hours (biological) | | Prednisolone | 4, 5 | 0.8 | 12 to 36 hours (biological) | | Dexamethasone | 25, 30 | ~0 | 36 to 54 hours (biological) |

Sources: FDA prescribing information for each agent; Brunton et al., Goodman and Gilman's Pharmacological Basis of Therapeutics [2].

Hydrocortisone (Cortef)

Hydrocortisone is bioidentical cortisol. At physiologic replacement doses of 15 to 25 mg/day in divided doses, it provides mild mineralocorticoid activity (roughly equivalent to 0.05 mg fludrocortisone), which is not sufficient for patients with primary adrenal insufficiency. Those patients require fludrocortisone added to hydrocortisone rather than a dose escalation of hydrocortisone, because escalating hydrocortisone to cover mineralocorticoid needs would produce glucocorticoid excess [3, 5]. Hydrocortisone's short biological half-life of 8 to 12 hours necessitates twice or three-times-daily dosing, making adherence a clinically relevant challenge [13].

Prednisone

Prednisone is a prodrug converted by hepatic 11-beta-hydroxysteroid dehydrogenase to the active metabolite prednisolone. Its glucocorticoid potency is approximately four times that of hydrocortisone, with minimal mineralocorticoid activity (0.8 relative to hydrocortisone) [2]. Prednisone is used for anti-inflammatory and immunosuppressive indications ranging from rheumatoid arthritis and asthma to organ transplantation, but it is not appropriate for mineralocorticoid replacement. Prednisone at doses exceeding 7.5 mg/day suppresses the hypothalamic-pituitary-adrenal (HPA) axis, a risk that underpins both the taper requirement and the risk of tertiary adrenal insufficiency after long-term use [14]. Abrupt discontinuation after more than 3 to 4 weeks of daily prednisone therapy risks adrenal crisis, which is why a structured taper is standard practice [15].

Prednisolone

Prednisolone is the active metabolite of prednisone and the preferred oral glucocorticoid in patients with hepatic insufficiency who cannot reliably convert prednisone. Its potency, mineralocorticoid activity, and HPA axis suppression profile are essentially identical to prednisone's on a milligram-per-milligram basis [2]. Prednisolone is also the corticosteroid most commonly used in pediatric practice because it is available as an oral liquid. In children with CAH, the Endocrine Society guideline recommends hydrocortisone over prednisolone or prednisone during growth years because longer-acting glucocorticoids carry greater risk of growth suppression [6].

Dexamethasone

Dexamethasone carries glucocorticoid potency approximately 25, 30 times that of hydrocortisone and essentially zero mineralocorticoid activity [2]. This combination makes it the agent of choice when pure glucocorticoid effect is needed without any fluid retention. Dexamethasone's long biological half-life of 36 to 54 hours provides sustained HPA axis suppression, which is why a single-dose dexamethasone suppression test (1 mg at 11 p.m.) is the standard screening tool for Cushing syndrome; a post-test morning serum cortisol above 1.8 mcg/dL has a sensitivity exceeding 95% [16]. Because dexamethasone provides no mineralocorticoid replacement, it cannot substitute for fludrocortisone in adrenal insufficiency. Long-term dexamethasone carries a high burden of glucocorticoid adverse effects including hyperglycemia, osteoporosis, and HPA suppression [17].

Monitoring Protocol During Fludrocortisone Therapy

Appropriate monitoring reduces the two most clinically significant complications of mineralocorticoid replacement: over-replacement (hypertension, hypokalemia, edema) and under-replacement (salt craving, fatigue, orthostatic hypotension, elevated plasma renin activity).

At initiation, check serum electrolytes and blood pressure after 4 to 6 weeks. Once the dose is stable, a practical monitoring schedule includes [5, 10]:

• Every 3 to 6 months: blood pressure (lying and standing), serum sodium and potassium, body weight.
• Every 6 to 12 months: plasma renin activity. The Endocrine Society guideline specifies targeting PRA in the upper half of the normal reference range as evidence of adequate, not excessive, mineralocorticoid effect.
• Annually: bone mineral density if the patient is also receiving long-term glucocorticoids, HbA1c in those with risk factors for diabetes.

Patients with primary adrenal insufficiency should carry a steroid emergency card and a pre-loaded hydrocortisone 100 mg injectable kit for sick-day management. Fludrocortisone dose does not typically need doubling during illness (unlike hydrocortisone), though sodium intake should increase with fever or gastrointestinal losses [5].

Sick-Day Rules and Adrenal Crisis Prevention

Adrenal crisis is a life-threatening emergency carrying a mortality rate of approximately 0.5 per 100 patient-years in patients with established Addison disease [18]. Vomiting prevents oral medication absorption, which is the most common precipitant of crisis.

Patients on fludrocortisone and hydrocortisone should be instructed to:

1. Double or triple the hydrocortisone dose (not fludrocortisone) at the onset of fever above 38°C or significant physical stress such as surgery.
2. Administer hydrocortisone 100 mg intramuscularly or intravenously if vomiting prevents oral dosing, then seek emergency care.
3. Wear a medical-alert bracelet identifying adrenal insufficiency.

A 2019 patient survey published in the European Journal of Endocrinology (N=1,245) found that only 51% of patients with primary adrenal insufficiency had received structured sick-day-rule education from their endocrinologist, and 28% had experienced at least one adrenal crisis in the preceding year [19].

Special Populations

Pregnancy. Primary adrenal insufficiency and CAH require continued mineralocorticoid and glucocorticoid replacement throughout pregnancy. Fludrocortisone is classified as FDA Pregnancy Category C (legacy classification) and is generally continued at pre-pregnancy doses. Plasma renin activity rather than blood pressure alone should guide dose adjustment because progesterone exerts anti-mineralocorticoid effects, often requiring fludrocortisone dose increases in the third trimester [20].

Older adults. Age-related declines in renal tubular function increase sensitivity to fludrocortisone-induced hypertension and hypokalemia. Starting at 0.05 mg/day and titrating slowly over 6 to 8 weeks reduces adverse event risk. The 2019 American Geriatrics Society Beers Criteria does not list fludrocortisone as a potentially inappropriate medication in older adults when used for an approved indication, distinguishing it from purely anti-inflammatory corticosteroids [21].

Heart failure. Expanded plasma volume in heart failure makes mineralocorticoid use complex. Fludrocortisone is relatively contraindicated in decompensated heart failure. When adrenal insufficiency coexists with compensated heart failure, the lowest effective dose with weekly blood pressure and weight monitoring is appropriate.